ATE145239T1 - Rns-katalysator zur spaltung von spezifischen rns-sequenzen - Google Patents

Rns-katalysator zur spaltung von spezifischen rns-sequenzen

Info

Publication number
ATE145239T1
ATE145239T1 AT89117424T AT89117424T ATE145239T1 AT E145239 T1 ATE145239 T1 AT E145239T1 AT 89117424 T AT89117424 T AT 89117424T AT 89117424 T AT89117424 T AT 89117424T AT E145239 T1 ATE145239 T1 AT E145239T1
Authority
AT
Austria
Prior art keywords
rna
catalyst
substrate
classification
specific
Prior art date
Application number
AT89117424T
Other languages
English (en)
Inventor
Arnold E Hampel
Richard H Tritz
Margaret F Hicks
Original Assignee
Univ Illinois
Biotechnology Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22933553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE145239(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Illinois, Biotechnology Res & Dev filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE145239T1 publication Critical patent/ATE145239T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Saccharide Compounds (AREA)
  • Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT89117424T 1988-09-20 1989-09-20 Rns-katalysator zur spaltung von spezifischen rns-sequenzen ATE145239T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24710088A 1988-09-20 1988-09-20

Publications (1)

Publication Number Publication Date
ATE145239T1 true ATE145239T1 (de) 1996-11-15

Family

ID=22933553

Family Applications (2)

Application Number Title Priority Date Filing Date
AT89117424T ATE145239T1 (de) 1988-09-20 1989-09-20 Rns-katalysator zur spaltung von spezifischen rns-sequenzen
AT95115981T ATE160584T1 (de) 1988-09-20 1989-09-20 Rns-katalysator zur spaltung von spezifischen rns-sequenzen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95115981T ATE160584T1 (de) 1988-09-20 1989-09-20 Rns-katalysator zur spaltung von spezifischen rns-sequenzen

Country Status (9)

Country Link
EP (3) EP0700996B1 (de)
JP (1) JP3167304B2 (de)
KR (1) KR900004937A (de)
AT (2) ATE145239T1 (de)
AU (3) AU641900B2 (de)
CA (1) CA1340323C (de)
DE (2) DE68928467T2 (de)
ES (2) ES2112006T3 (de)
GR (2) GR3022403T3 (de)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4091533T (de) * 1989-08-31 1992-01-30
GB9018646D0 (en) * 1990-08-24 1990-10-10 Imperial College Replication of a eukaryotic virus rna
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
KR100260483B1 (ko) * 1992-04-17 2000-07-01 마나배 게이사꾸 Rna 비루스에 대하여 저항성을 갖는 식물 제조방법
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
CA2139411A1 (en) * 1992-07-02 1994-01-20 Eiko Otsuka Ribozyme having a thermodynamically stable loop
US5891684A (en) * 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5422253A (en) * 1992-12-07 1995-06-06 Wisconsin Alumni Research Foundation Method of site specific nucleic acid cleavage
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
CN1127527A (zh) * 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
EP1602725A3 (de) * 1993-09-02 2006-03-29 Sirna Therpeutics, Inc. Enzymatische Nukleinsäure die Abasische Nukleotide enthaltet
ATE174600T1 (de) * 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
EP0728204A1 (de) 1993-11-08 1996-08-28 Ribozyme Pharmaceuticals, Inc. Enzymatische nukleinsaeure mit modifizierten bosen
US5631359A (en) * 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6350934B1 (en) 1994-09-02 2002-02-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid encoding delta-9 desaturase
US5672501A (en) * 1994-12-23 1997-09-30 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5705388A (en) * 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US5663064A (en) * 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
US5872241A (en) * 1995-01-25 1999-02-16 The Trustees Of Columbia University In The City Of New York Multiple component RNA catalysts and uses thereof
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
EP0842286A2 (de) * 1995-07-13 1998-05-20 Ribozyme Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur modulation der pflanzengenexpression
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0907746B1 (de) 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6057156A (en) * 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6159951A (en) * 1997-02-13 2000-12-12 Ribozyme Pharmaceuticals Inc. 2'-O-amino-containing nucleoside analogs and polynucleotides
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6183959B1 (en) 1997-07-03 2001-02-06 Ribozyme Pharmaceuticals, Inc. Method for target site selection and discovery
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
AU754803B2 (en) 1997-09-16 2002-11-28 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
DE69830663T2 (de) 1997-09-24 2006-05-11 The Regents Of The University Of California, Oakland Nicht-Primaten-Lentivirus-Vektoren und Verpackungssysteme
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
AU1671199A (en) 1997-11-18 1999-06-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acids involved in the responder phenotype and applications thereo
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
EP2336337B1 (de) 1998-11-12 2015-07-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Chimäre Promotoren, befähigt zur Vermittlung der Genexpression in Pflanzen bei Infektion mit Pathogenen sowie deren Verwendungen
CA2352532C (en) 1998-11-27 2014-10-14 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
WO2000066780A2 (en) 1999-04-30 2000-11-09 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
ES2250173T3 (es) 1999-07-20 2006-04-16 Gvs Gesellschaft Fur Erwerb Und Verwertung Von Schutzrechten Mbh Nuevo metodo para la generacion y seleccion de plantas de linaza o lino transgenicas.
WO2005041859A2 (en) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery.
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
EP1319069B1 (de) 2000-06-28 2008-05-21 Corixa Corporation Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
CA2433806C (en) 2001-01-09 2011-03-15 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
JP4353701B2 (ja) 2001-05-08 2009-10-28 ダーウィン モレキュラー コーポレイション Ｆｏｘｐ３蛋白質を用いた霊長類における免疫機能の調節方法
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP2415486B1 (de) 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Konjugate und Zusammensetzungen zur zellulären Verabreichung
US8022272B2 (en) 2001-07-13 2011-09-20 Sungene Gmbh & Co. Kgaa Expression cassettes for transgenic expression of nucleic acids
US7456335B2 (en) 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
US6939959B2 (en) 2001-10-26 2005-09-06 Id Biomedical Corporation Of Washington Efficient protein expression system
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
DE10212892A1 (de) 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
EP2368431A1 (de) * 2002-04-04 2011-09-28 Coley Pharmaceutical GmbH Immunstimulierende G,U-haltige Oligoribonucleotide
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2004003150A2 (en) 2002-06-26 2004-01-08 Yale University Modulators and modulation of the interacton between rgm and neogenin
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
CA2492472C (en) 2002-07-18 2014-01-07 Helix Biopharma Corp. Use of urease for inhibiting cancer cell growth
US7786344B2 (en) 2002-07-26 2010-08-31 Basf Plant Science Gmbh Selection method
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
AU2003288906C1 (en) 2002-09-20 2010-12-09 Yale University Riboswitches, methods for their use, and compositions for use with riboswitches.
AU2004210975B2 (en) 2003-02-10 2008-04-10 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
JP2004261017A (ja) * 2003-02-27 2004-09-24 Arkray Inc クラミジア・トラコマティスの検出方法およびそのためのキット
ATE541052T1 (de) 2003-05-30 2012-01-15 Agensys Inc Varianten des prostata-stammzellen-antigens (psca) und teilsequenzen davon
EP1689888A2 (de) 2003-10-23 2006-08-16 Illumigen Biosciences Inc. Nachweis von mutationen in einem mit der resistenz gegenüber einer virusinfektion assoziierten gen, oas1
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
JP4651663B2 (ja) 2004-05-28 2011-03-16 アジェンシス，インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
CA2834275A1 (en) 2004-08-02 2006-02-09 Basf Plant Science Gmbh Method for isolation of transcription termination sequences
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP1794304B1 (de) 2004-09-24 2013-06-19 BASF Plant Science GmbH Pflanzenzellen und pflanzen mit erhöhter umweltstresstoleranz
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
AU2006311089C1 (en) 2005-11-08 2012-11-08 Basf Plant Science Gmbh Use of armadillo repeat (ARM1) polynucleotides for obtaining pathogen resistance in plants
EP1974052A2 (de) 2005-12-21 2008-10-01 Yale University Verfahren und zusammensetzungen in verbindung mit der modulation von riboschaltern
US8178751B2 (en) 2006-01-12 2012-05-15 Basf Plant Science Gmbh Use of stomatin (STM1) polynucleotides for achieving a pathogen resistance in plants
EP2090662A3 (de) 2006-04-05 2012-10-31 Metanomics GmbH Verfahren zur Herstellung einer feinen Chemikalie
EP2010226B1 (de) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
EP2030021B1 (de) 2006-05-18 2012-11-21 Andreas Reichert Verfahren zur diagnose mitochondrialer fehlfunktion
CA2673361A1 (en) 2007-01-15 2008-07-24 Basf Plant Science Gmbh Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants
US20110035840A1 (en) 2007-02-16 2011-02-10 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledoneous plants
AU2008252998A1 (en) 2007-05-22 2008-11-27 Basf Plant Science Gmbh Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-KO
EP2040075A1 (de) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Verbindungen und Marker für oberflächenverstärkte Raman-Streuung
CA2708153C (en) 2007-12-04 2017-09-26 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
DE112008003433T5 (de) 2007-12-21 2010-11-04 Basf Plant Science Gmbh Pflanzen mit erhöhtem Ertrag (KO NUE)
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
EP2184351A1 (de) 2008-10-30 2010-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polynukleotid-kondierende Caryophyllen-Synthase und ihre Verwendung
CA2743136C (en) 2008-11-10 2019-02-26 Muthiah Manoharan Novel lipids and compositions for the delivery of therapeutics
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
EP2421976B1 (de) 2009-04-22 2015-09-16 BASF Plant Science Company GmbH Für ganze samen spezifischer promotor
EP3504967A1 (de) 2009-05-05 2019-07-03 Arbutus Biopharma Corporation Verfahren zur abgabe von oligonukleotiden an immunzellen
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
EP2440183B1 (de) 2009-06-10 2018-07-18 Arbutus Biopharma Corporation Verbesserte lipidformulierung
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
CN102812014B (zh) 2009-10-30 2016-01-20 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途
EP3296398A1 (de) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Zusammensetzungen für nukleinsäurefreisetzung
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
KR101984145B1 (ko) 2010-04-23 2019-05-30 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 레베르 선천성 흑내장-1(lca-1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법
US8476485B2 (en) 2010-06-24 2013-07-02 Academia Sinica Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
SG10201508118WA (en) 2010-09-30 2015-11-27 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
ES2818586T3 (es) 2011-02-07 2021-04-13 Governing Council Univ Toronto Biosondas y métodos de uso de las mismas
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP3456317B1 (de) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Substituierte di-aliphatic pegylierte lipide
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
EP2666775A1 (de) 2012-05-21 2013-11-27 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
WO2014127835A1 (en) 2013-02-22 2014-08-28 Christian-Albrechts-Universität Zu Kiel Plant-derived resistance gene
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3000814A1 (de) 2014-09-26 2016-03-30 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
CN114901253A (zh) 2019-08-14 2022-08-12 爱康泰生治疗公司 用于递送核酸的改进的脂质纳米颗粒
JP7709981B2 (ja) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
WO2022133344A1 (en) 2020-12-18 2022-06-23 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
CA3212944A1 (en) 2021-03-31 2022-10-06 Patrick Dougherty Cyclic cell penetrating peptides
JP2024518068A (ja) 2021-05-10 2024-04-24 エントラーダ セラピューティクス，インコーポレイティド 細胞内治療のための組成物及び方法
US20250051393A1 (en) 2021-05-10 2025-02-13 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
US20250051780A1 (en) 2021-05-10 2025-02-13 Entrada Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
GEAP202416440A (en) 2021-06-23 2024-04-25 Entrada Therapeutics Inc Antisense compounds and methods for targeting cug repeats
CA3227661A1 (en) 2021-08-05 2023-02-09 Weimin Wang 1'-alkyl modified ribose derivatives and methods of use
CN118076619A (zh) 2021-09-22 2024-05-24 美国圣因生物股份有限公司 用于寡核苷酸的体内递送的2′-烷基或3′-烷基修饰的核糖衍生物
WO2023059695A1 (en) 2021-10-05 2023-04-13 Sanegene Bio Usa Inc. Polyhydroxylated cyclopentane derivatives and methods of use
JP2025504682A (ja) 2022-01-31 2025-02-14 ジェネバント サイエンシズ ゲーエムベーハー ポリ（アルキルオキサゾリン）－脂質コンジュゲートおよびそれを含む脂質粒子
CA3250180A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES
IL314850A (en) 2022-02-22 2024-10-01 Sanegene Bio Usa Inc Ribonucleotide derivatives substituted at the 5' position in the carboxyl group and methods of use
US20240218363A1 (en) 2022-07-11 2024-07-04 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use
AU2024265206A1 (en) 2023-05-03 2025-11-06 Sanegene Bio Usa Inc. Lipid-based conjugates for systemic, central nervous system, peripheral nervous system, and ocular delivery
WO2025024523A1 (en) 2023-07-24 2025-01-30 Sanegene Bio Usa Inc. Lipid-based enhancement agent for rna delivery and therapy
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340831C (en) * 1987-12-15 1999-11-30 Wayne Lyle Gerlach Ribozymes

Also Published As

Publication number Publication date
DE68928467D1 (de) 1998-01-08
AU4420793A (en) 1993-12-02
JP3167304B2 (ja) 2001-05-21
DE68927456D1 (de) 1996-12-19
KR900004937A (ko) 1990-04-13
CA1340323C (en) 1999-01-19
DE68927456T2 (de) 1997-03-20
ES2095210T3 (es) 1997-02-16
AU2850395A (en) 1996-03-28
AU4159489A (en) 1990-03-29
EP0700996B1 (de) 1997-11-26
GR3026045T3 (en) 1998-05-29
EP0360257B1 (de) 1996-11-13
AU691007B2 (en) 1998-05-07
JPH03123485A (ja) 1991-05-27
EP0700996A1 (de) 1996-03-13
ES2112006T3 (es) 1998-03-16
DE68928467T2 (de) 1998-03-19
EP0360257A3 (de) 1991-04-17
EP0360257A2 (de) 1990-03-28
GR3022403T3 (en) 1997-04-30
AU659330B2 (en) 1995-05-11
ATE160584T1 (de) 1997-12-15
EP0812912A1 (de) 1997-12-17
AU641900B2 (en) 1993-10-07

Similar Documents

Publication Publication Date Title
ATE160584T1 (de) Rns-katalysator zur spaltung von spezifischen rns-sequenzen
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
EP0739980A3 (de) CD 19 Kodierende DNA
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
IL211788A0 (en) Wnt-1 induced secreted polypeptides: wisp-1', -2 and -3
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
EA199900503A1 (ru) Днк, кодирующая активные дельта-эндотоксины чешуекрылых насекомых, и ее использование
KR960010863A (ko) 재조합 머사시딘 및 이의 제조방법
DE3683447D1 (de) Verfahren zur herstellung von humanlysozym.
ID22037A (id) PROSES REKOMBINAN UNTUK MEMBUAT ANTIGEN MALARIA KOMPLET gp190/MSPI
PT97427A (pt) Processo para a preparacao de proteinas de fusao de tendamistato em estreptomicetas
DE69934017D1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
DE3584029D1 (de) Expressionsvektoren, dns-fragmente, peptide, wirte und verfahren zur herstellung von peptiden.
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
WO1987007472A3 (en) A dna sequence encoding the mas oncogene, polypeptides encoded therefrom, and diagnostic and other methods based thereon
EP0688224A4 (de) Ein mutiertes protein und verfahren und materialien zu seiner herstellung und verwendung
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
EP1241186A3 (de) Menschliches gas-6 (growth arrest-specific gene 6) Protein und dafür kodierende Nukleinsäure
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen
KR930701464A (ko) 이질성 단백질의 생성용 스트렙토마이세스 벡터
DK1029046T3 (da) WNT-1 inducerbare gener
DK1217006T3 (da) Polypeptider og nucleinsyrer kodende for samme
ATE319821T1 (de) Verfahren und produkt zur regulation der reaktionsempfindlichkeit von zellen auf externe signale

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee